Carisma Therapeutics, Inc. (NASDAQ:CARM) Receives Consensus Recommendation of “Hold” from Analysts

Carisma Therapeutics, Inc. (NASDAQ:CARM) has received a consensus recommendation of “Hold” from the seven research firms that are currently covering the firm, MarketBeat Ratings reports. Five investment analysts have rated the stock with a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $4.94.

Several analysts have recently issued reports on CARM shares. HC Wainwright reissued a “neutral” rating on shares of Carisma Therapeutics in a research note on Monday, December 16th. Robert W. Baird downgraded Carisma Therapeutics from an “outperform” rating to a “neutral” rating and lowered their price target for the company from $10.00 to $1.00 in a research report on Thursday, December 12th. Evercore ISI restated an “in-line” rating and issued a $0.70 price objective (down from $4.00) on shares of Carisma Therapeutics in a report on Wednesday, December 11th. EF Hutton Acquisition Co. I raised Carisma Therapeutics to a “strong-buy” rating in a research note on Wednesday, October 30th. Finally, Baird R W downgraded shares of Carisma Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, December 12th.

Hedge Funds Weigh In On Carisma Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CARM. Barclays PLC lifted its stake in shares of Carisma Therapeutics by 3,661,933.3% in the third quarter. Barclays PLC now owns 549,305 shares of the company’s stock worth $539,000 after acquiring an additional 549,290 shares in the last quarter. Wexford Capital LP increased its holdings in Carisma Therapeutics by 75.5% during the 3rd quarter. Wexford Capital LP now owns 34,861 shares of the company’s stock worth $34,000 after purchasing an additional 15,000 shares during the last quarter. Finally, Renaissance Technologies LLC raised its position in shares of Carisma Therapeutics by 11.9% in the 4th quarter. Renaissance Technologies LLC now owns 231,357 shares of the company’s stock valued at $97,000 after purchasing an additional 24,600 shares in the last quarter. 44.27% of the stock is owned by hedge funds and other institutional investors.

Carisma Therapeutics Price Performance

Carisma Therapeutics stock opened at $0.44 on Tuesday. Carisma Therapeutics has a 1 year low of $0.38 and a 1 year high of $2.77. The company has a debt-to-equity ratio of 1.39, a quick ratio of 3.23 and a current ratio of 3.23. The firm has a 50 day moving average price of $0.46 and a 200 day moving average price of $0.78. The company has a market cap of $18.45 million, a price-to-earnings ratio of -0.28 and a beta of 1.56.

About Carisma Therapeutics

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.